— New data demonstrate efficacy for the oral treatment combination to address MET-driven resistance in EGFR-mutated lung cancer — — MET is a common biomarker in this setting for patients who develop resistance to EGFR targeted therapies — HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Oct. 16, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces positive high-level results from the SAVANNAH Phase II trial that showed TAGRISSO® (osimertinib) plus ORPATHYS ...

Shares of HUTCHMED (China) Ltd (HCM, Financial) surged 2.90% in mid-day trading on Oct 2. The stock reached an intraday high of $21.10, before settling at $20.58, up from its previous close of $20.00. This places HCM 6.11% below its 52-week high of $21.92 and 72.44% above its 52-week low of $11.93. Trading volume was 210,051 shares, 216.8% of the average daily volume of 96,867. Wall Street Analysts Forecast Based on the one-year price targets offered by 12 analysts, the average target price for HUTCHMED (Ch ...

Patient randomization is underway in SONATA-HCM clinical trial evaluating Lexicon’s novel dual SGLT1 and SGLT2 inhibitor in this underserved and growing patient population  Study design intended to enable supplemental new drug application (sNDA) with a broad label in both obstructive and non-obstructive HCM THE WOODLANDS, Texas, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it will unveil study design details of SONATA-HCM, the company’s Phase 3 clinica ...

— Approval based on results from global Phase III FRESCO-2 trial in patients with previously treated metastatic colorectal cancer — — Fruquintinib already approved in several regions including the United States, Europe and China — HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Sept. 24, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that its partner Takeda (TSE:​4502/​NYSE:​TAK) has received approval from the Japanese Ministry of Health, Labour and ...

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Sept. 09, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the 2024 World Conference on Lung Cancer (“WCLC24”) in San Diego, USA, and the European Society for Medical Oncology (“ESMO”) Congress 2024, taking place in Barcelona, Spain. Results from the FLOWERS study, a prospective, two-arm, randomized, mul ...

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Aug. 30, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that it has voluntarily withdrawn its supplemental New Drug Application (“NDA”) in China for fruquintinib in combination with paclitaxel for the treatment of second-line advanced gastric or gastroesophageal junction adenocarcinoma and will evaluate a new route forward. Following an additional internal review of the current data package, in light o ...

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Aug. 21, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it will host a physician expert call with a professor and key opinion leader in immune thrombocytopenia (“ITP”), to discuss the treatment landscape of ITP via webcast on Wednesday, August 28, 2024, at 7:00 p.m. HKT. The event will be held in Chinese (Putonghua) and can be accessed via www.hutch-med.com/event. Investors interested in listening t ...

AUSTIN, Texas, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Asure (NASDAQ: ASUR), a leading provider of cloud-based Human Capital Management (HCM) software solutions, has acquired HireClick, an innovative hiring solution designed to streamline the recruitment process for small and mid-sized businesses. This strategic acquisition reinforces Asure’s commitment to delivering comprehensive, user-friendly tools that simplify people management. "Hiring top talent is an essential component of running a successful business, n ...

Financial Performance - The total comprehensive revenue for the oncology/immunology business was $168.7 million, down from $359.2 million in the first half of 2023[15]. - Total revenue decreased by 43% to $305.7 million in the first half of 2024, down from $532.9 million in the same period of 2023[16]. - The comprehensive net profit attributable to Hutchison China MediTech's other businesses decreased by 8% to $34.1 million, mainly due to reduced contributions from Shanghai Hutchison Pharmaceuticals[33]. - The company reported a significant decline in service revenue, which fell by 87% to $33.8 million in the first half of 2024[16]. - The net income attributable to the company was $25.8 million, down from $168.6 million in the first half of 2023, representing a decrease of approximately 84.7%[43]. - The company reported a net loss of $4.8 million before tax expenses and equity earnings, compared to a profit of $137.1 million in the first half of 2023[43]. - The total comprehensive income for the six months ended June 30, 2024, was $305.7 million, a decrease of 43% compared to $532.9 million in 2023[128]. - The revenue from the oncology/immunology business was $168.7 million, down 53% from $359.2 million in the previous year[128]. Oncology Product Sales - The oncology business market sales increased by 140% to $243.3 million, with a comprehensive revenue growth of 59% to $127.8 million compared to the first half of 2023[15]. - The sales of ORPATHYS® (savolitinib) grew by 18% to $25.9 million, driven by advancements in MET exon 14 skipping mutation testing and continued growth momentum after inclusion in the national health insurance drug list[15]. - FRUZAQLA® achieved market sales of $130.5 million in the first half of 2024, a significant increase from $0 in the same period of 2023[16]. - ELUNATE® (爱优特®) market sales grew by 8% to $61.0 million, with a 13% increase at fixed exchange rates, compared to $56.3 million in the first half of 2023[17]. - SULANDA® (苏泰达®) market sales increased by 12% to $25.4 million, reflecting a 17% growth at fixed exchange rates, up from $22.6 million in the first half of 2023[17]. - The sales of innovative oncology products by the company grew by 140% to $243.3 million in the first half of 2024, driven primarily by the launch of FRUZAQLA®[46]. - The sales of 爱优特® in China reached $61 million in the first half of 2024, an 8% increase from $56.3 million in the same period of 2023[49]. - The sales of 索凡替尼 (苏泰达®) increased by 12% to $25.4 million in the first half of 2024, maintaining a 21% prescription share in the neuroendocrine tumor treatment market[52]. - The sales of 沃瑞沙® reached $25.9 million in the first half of 2024, an 18% increase from $22 million in the same period of 2023[53]. Research and Development - The company has initiated three key late-stage studies this year, with over ten critical studies currently ongoing in the pipeline[13]. - The company plans to submit a new drug application for EZH240 in mid-2025 for the treatment of relapsed/refractory follicular lymphoma[26]. - The company is actively recruiting patients for the SACHI study, expected to complete by the end of 2024[24]. - The company has 13 oncology candidates currently in clinical trials, with three drugs already approved in mainland China[45]. - The company is expanding its product pipeline with new indications for existing drugs, including applications for endometrial cancer and non-small cell lung cancer[22]. - The company has initiated a Phase III study for IDH1/2 mutant relapsed/refractory acute myeloid leukemia in China[30]. - The company has initiated a phase II/III trial for savolitinib combined with chemotherapy in previously untreated metastatic pancreatic cancer, with an additional 500 patients expected to be recruited[86]. - The company supports approximately 130 clinical trials for the investigational drug Surufatinib in China, focusing on various solid tumors[88]. Regulatory Approvals - The company expects to achieve registration approval for solitomab in China by the end of the year and plans to submit a new drug application for savolitinib in the U.S.[13]. - The company received positive opinions from the European Medicines Agency for FRUZAQLA® in April 2024, leading to its approval in the EU in June 2024[19]. - The company plans to submit a new drug application to the FDA based on the SAVANNAH study results by the end of 2024, pending positive outcomes[24]. - The new indication for Savolitinib for treating locally advanced or metastatic non-small cell lung cancer with MET exon 14 alteration has been accepted for review by the National Medical Products Administration in March 2024[67]. Financial Position - The cash and cash equivalents totaled $802.5 million as of June 30, 2024, down from $886.3 million at the end of 2023[35]. - Total liabilities decreased to $508.9 million as of June 30, 2024, from $536.4 million at the end of 2023[41]. - The company’s cash and cash equivalents and short-term investments totaled $802.5 million as of June 30, 2024, down from $886.3 million at the end of 2023[41]. - The company has utilized RMB 405.5 million ($55.6 million) from a 10-year fixed asset loan agreement with Bank of China as of June 30, 2024[139]. - The company has a capital commitment of $1.6 million for property, plant, and equipment as of June 30, 2024[143]. - The company has no outstanding bank loans from its non-consolidated joint venture, Shanghai Hutchison Pharmaceuticals, as of June 30, 2024[139]. - The company has not paid dividends from Shanghai Hutchison Pharmaceuticals in the first half of 2024, compared to $14.6 million in the same period of 2023[123]. Shareholder Information - The largest shareholder, CK Hutchison Global Investments Limited, holds 332,574,650 shares, accounting for 38.17% of the total shares[175]. - The company has a total of 332,478,770 shares held by Hutchison Healthcare Holdings Limited, which also represents 38.16% of the total shares[175]. - The total number of shares held by the beneficial owner, Su Weiguo, is 10,125,817, which includes options that may convert into shares upon meeting vesting conditions[174]. - The total number of shares held by the directors includes 19,000 ordinary shares and 22,456 American Depositary Shares (ADS), with each ADS equivalent to five shares[174]. - The company has a total of 69,688,835 shares held by Deutsche Bank Aktiengesellschaft, representing approximately 8.01% of the total shares[175]. Employee and Incentive Plans - The company employed approximately 1,970 full-time employees as of June 30, 2024, with total employee expenses amounting to USD 101.9 million for the six months ended June 30, 2024[163]. - The company has established a strategic partnership with Chuangxiang Biotech to develop innovative clinical candidates for autoimmune diseases, with a 7.5% equity stake acquired in July 2024[111]. - The long-term incentive plan aims to attract and retain skilled personnel, with rewards linked to performance metrics and vesting schedules[190][191]. - The company has a long-term incentive plan that includes non-performance-related rewards, with vesting occurring on specified dates[197].

Thomas Barwick/DigitalVision via Getty Images Hutchmed logo (Hutchmed)Investment Thesis In our article on HUTCHMED (China) Limited (NASDAQ:HCM) on the 26th of March this year, we continued our Buy stance on the back of our expectations that the company finally is becoming profitable. The share price is up nearly 20%. HCM’s colon cancer drug FRUZAQLA’s approval by the U.S. FDA at the end of last year was a game-changer for the company with a reported good uptake from U.S. patients after the launch. We b ...